How many 8-K filings has Outlook Therapeutics, Inc. filed?

Outlook Therapeutics, Inc. (OTLK) has 35 8-K (Current Event Report) filings on record, spanning Jan 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Outlook Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Outlook Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Outlook Therapeutics, Inc. (OTLK) — 8-K Filings

All 8-K filings from Outlook Therapeutics, Inc.. Browse 35 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (35)

Outlook Therapeutics Files 8-K: Other Events — Nov 13, 2025 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
Outlook Therapeutics Files 8-K — Nov 3, 2025 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on November 3, 2025, reporting other events and financial statements. The company, formerly known as Oncobiologics, Inc.
Outlook Therapeutics Files 8-K — Sep 29, 2025 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on September 29, 2025, reporting other events and financial statements. The company, formerly known as Oncobiologics, In
Outlook Therapeutics Relocates HQ, Reports Officer/Director Changes — Sep 5, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on September 5, 2025, a change in its principal executive offices to 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 0883
Outlook Therapeutics Files 8-K — Sep 2, 2025 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting other events and financial statements. The company, formerly known as Oncobiologics, Inc.,
Outlook Therapeutics Files 8-K on Financials — Aug 14, 2025 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
Outlook Therapeutics Appoints New Chief Medical Officer — Jul 1, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on June 28, 2025, the appointment of Dr. Paul E. Chaney as Chief Medical Officer. Dr. Chaney brings extensive experience in
Outlook Therapeutics Sells ONS-5010 Assets — Jun 2, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on June 2, 2025, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-tnv) assets to a third p
Outlook Therapeutics Files 8-K — May 23, 2025 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting an event on May 22, 2025. The filing is categorized under 'Other Events' and 'Financial State
Outlook Therapeutics Files 8-K on Financials — May 15, 2025 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Outlook Therapeutics Appoints New Chief Medical Officer — Apr 11, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on April 9, 2025, the appointment of Dr. Paul E. Chaney as Chief Medical Officer. Dr. Chaney brings extensive experience in
Outlook Therapeutics Sells ONS-5010 for $10M Cash — Apr 8, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on April 8, 2025, that it has entered into a definitive agreement to sell its ONS-5010 (lytenru) product candidate to a thi
Outlook Therapeutics Files 8-K on Key Corporate Events — Mar 14, 2025 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on several events as of March 11, 2025. These include the termination of a material definit
Outlook Therapeutics Prices $10M Private Placement — Feb 28, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on February 28, 2025, that it has entered into a securities purchase agreement with an institutional investor for a private
Outlook Therapeutics Files 8-K on Financials — Feb 14, 2025 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on February 14, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
Outlook Therapeutics Files 8-K: Agreements, Financial Obligations, and Officer Changes — Jan 31, 2025 Risk: medium
Outlook Therapeutics, Inc. announced on January 30, 2025, that it entered into a material definitive agreement and incurred a direct financial obligation. The c
Outlook Therapeutics Files 8-K with Key Corporate Updates — Jan 16, 2025 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting on several events including the entry into a material definitive agreement, unregistered
Outlook Therapeutics Files 8-K on Financials — Dec 27, 2024 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on December 27, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
Outlook Therapeutics Sells ONS-5010 Assets — Dec 16, 2024 Risk: medium
Outlook Therapeutics, Inc. reported on December 10, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab) assets to a third p
Outlook Therapeutics Appoints New CMO, Director — Dec 4, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on December 3, 2024, the appointment of Dr. Paul Ashton as Chief Medical Officer and the election of Ms. Karen Smith to its
Outlook Therapeutics Files 8-K — Nov 27, 2024 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on November 27, 2024, reporting other events and financial statements. The company, formerly known as Oncobiologics, Inc
Outlook Therapeutics Sells ONS-5010 for $15M+ — Aug 14, 2024 Risk: high
Outlook Therapeutics, Inc. announced on August 14, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab) product candidate to
Outlook Therapeutics Sells ONS-5010 Assets for $15M+ — Jul 8, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on July 8, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-vikg) assets to a third
Outlook Therapeutics Sells ONS-5010 Assets — May 28, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on May 28, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-vikg) assets to a third
Outlook Therapeutics Sells ONS-5010 for $15M — May 15, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on May 15, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab) product candidate to a
Outlook Therapeutics Sells ONS-5010 for $10M Cash — May 13, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on May 13, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab) product candidate to a
Outlook Therapeutics Partners with Syner-Med for ONS-5010 Launch — May 1, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on May 1, 2024, that it has entered into a strategic collaboration with Syner-Med, Inc. This collaboration aims to support
Outlook Therapeutics Raises $10M in Stock Offering — Apr 15, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on April 15, 2024, that it entered into a securities purchase agreement for the sale of approximately $10.0 million of its
Outlook Therapeutics Sells ONS-5010 Assets — Apr 12, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on April 12, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-vikg) assets to a thir
Outlook Therapeutics Partners with Syner-Med for ONS-5010 Launch — Apr 2, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on April 1, 2024, that it has entered into a strategic collaboration with Syner-Med, Inc. to support the commercialization
Outlook Therapeutics Appoints New Chief Medical Officer — Mar 26, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on March 20, 2024, the appointment of Dr. Lawrence M. Feinberg as Chief Medical Officer. Dr. Feinberg brings extensive expe
Outlook Therapeutics Raises $10M in Registered Direct Offering — Mar 18, 2024 Risk: medium
Outlook Therapeutics, Inc. announced on March 13, 2024, that it entered into a securities purchase agreement for the sale of approximately $10.0 million of its
Outlook Therapeutics Files 8-K with Corporate Updates — Mar 7, 2024 Risk: medium
Outlook Therapeutics, Inc. filed an 8-K on March 7, 2024, reporting on several key items. These include amendments to its articles of incorporation or bylaws, t
Outlook Therapeutics Files 8-K on Financial Condition and Results — Feb 14, 2024 Risk: low
Outlook Therapeutics, Inc. filed an 8-K on February 14, 2024, to report on its Results of Operations and Financial Condition, along with Financial Statements an
Outlook Therapeutics Reports Material Agreement, Equity Sales — Jan 24, 2024
Outlook Therapeutics, Inc. filed an 8-K on January 24, 2024, reporting an event that occurred on January 22, 2024, related to an entry into a material definitiv

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX